National Radiology Data Registry

QCDR Report, September 2016

Public Facility

(Facility ID: 100853)

NRDR
NMD®
NATIONAL MAMMOGRAPHY DATABASE
AMERICAN COLLEGE OF RADIOLOGY

nrdr.acr.org

NRDR
CTC™
CT COLONOGRAPHY REGISTRY
AMERICAN COLLEGE OF RADIOLOGY

NRDR
DIR®
DOSE INDEX REGISTRY
AMERICAN COLLEGE OF RADIOLOGY

NRDR
GRID™
GENERAL RADIOLOGY IMPROVEMENT DATABASE
AMERICAN COLLEGE OF RADIOLOGY

NRDR
LCSR™
LUNG CANCER SCREENING REGISTRY
AMERICAN COLLEGE OF RADIOLOGY

Breast Cancer Surveillance Consortium

BCSC

Working together to advance breast cancer research

NMD QCDR Measure Definitions

Measure	Definition
All exams	Number of screening exams performed
ACRad 3: Cancers and CDR per 1000	Number of screening mammograms with a BI-RADS assessment category of 0, 4 or 5, total and per 1000, that had a tissue diagnosis of cancer within 12 months.
ACRad 4: Invasive CDR per 1000	Number of screening mammograms with a BI-RADS assessment category of 0, 4 or 5, total and per 1000, that had a tissue diagnosis of invasive cancer within 12 months. (Invasive cancer rate x CDR)
ACRad 5: Recall rate	Number and percent of screening exams with a BI-RADS assessment category of 0, 3,4 or 5.
ACRad 6: Cancers and PPV2	Number of screening exams and percent of screening exams where biopsy was recommended that result in a tissue diagnosis of cancer within 12 months.
Invasive cancer	Number and percent of cancers that were invasive
ACRad 7: Nodal status - negative	Number and percent of exams with nodal status indicated where status was negative
ACRad 8: Minimal cancer	Number and percent of cancers that were DCIS or had a tumor size of 10mm or less
PQRS 146: Inappropriate use of BI-RADS	Number and percent of screening exams with a BI-RADS assessment category of 3.

Section 1:Outcome measures and demographic data for exams with at least 365 days follow-up (Includes uploaded follow up data through September 30, 2016)

*(Facilities with no exams with at least 365 days follow-up receive only NMD aggregate and benchmark data in this section.
Preliminary data for the facility are available in Section 2.)*

QCDR Measures: Abnormal Interpretations and Cancers for Screening Mammography
January 2015 - December 2015: Comparison to all NMD facilities and BCSC benchmarks
Follow up available through September 30, 2016

	Facility 100853			All NMD facilities (N=274)			BCSC benchmark*		
Measure	Rate	(Num-Den)		Rate	(Num-Den)		Rate	(Num-Den)	
All exams	.	.	10,214	.	.	2,359,219	.	.	2,410,932
ACRad 5: Abnormal interpretation and recall rate	.	11.02%	(1,126 /10,214)	.	10.00%	(235,908 /2,359,219)	.	10.95%	(263,905 /2,410,932)
ACRad 6: Cancers and PPV2	.	28.75%	(23 /80)	.	21.30%	(7,868 /36,946)	.	22.90%	(7,613 /33,239)
ACRad 3: Cancers and CDR per 1000	.	2.45	(25 /10,214)	.	4.16	(9,805 /2,359,219)	.	4.18	(10,072 /2,410,932)
ACRad 4: Invasive cancers and ICDR per 1000	.	2.45	(25 /10,214)	.	3.13	(7,396 /2,359,219)	.		
Invasive cancer rate (Used to calculate ICDR)	.	100.00%	(25 /25)	.	75.48%	(7,396 /9,798)	.	76.42%	(7,697 /10,072)
ACRad 8: Minimal cancer rate	.	.%	(/)	.	72.62%	(3,830 /5,274)	.	52.40%	(4,980 /9,504)
ACRad 7: Nodal status negative rate	.	0.00%	(0 /21)	.	87.60%	(3,023 /3,451)	.	75.95%	(5,629 /7,411)
PQRS 146: Inappropriate use of BI-RADS 3	.	0.29%	(30 /10,214)	.	0.29%	(6,775 /2,359,100)	.		

To learn more about the Qualified Clinical Data Registry (QCDR) option please click below
http://www.acr.org/Quality-Safety/National-Radiology-Data-Registry/Qualified-Clinical-Data-Registry
NCI-funded Breast Cancer Surveillance Consortium (BCSC) data on screening mammograms performed 2002-2006.
*BCSC benchmark data are calculated using screen-detected cancers; NMD data may include some interval cancers.

QCDR Measures: Abnormal Interpretations and Cancers for Screening Mammography
Physician 1013909175: January 2015 - December 2015
Follow up available through September 30, 2016

Measure	1013909175			Facility 100853			All NMD facilities (N=274)			BCSC benchmark*		
		Rate	(Num-Den)		Rate	(Num-Den)		Rate	(Num-Den)		Rate	(Num-Den)
All exams	.	.	146	.	.	10,214	.	.	2,359,219	.	.	2,410,932
ACRad 5: Abnormal interpretation and recall rate	.	16.44%	(24 /146)	.	11.02%	(1,126 /10,214)	.	10.00%	(235,908 /2,359,219)	.	10.95%	(263,905 /2,410,932)
ACRad 6: Cancers and PPV2	.	0.00%	(0 /2)	.	28.75%	(23 /80)	.	21.30%	(7,868 /36,946)	.	22.90%	(7,613 /33,239)
ACRad 3: Cancers and CDR per 1000	.	0.00	(0 /146)	.	2.45	(25 /10,214)	.	4.16	(9,805 /2,359,219)	.	4.18	(10,072 /2,410,932)
ACRad 4: Invasive cancers and ICDR per 1000	.	0.00	(0 /146)	.	2.45	(25 /10,214)	.	3.13	(7,396 /2,359,219)	.		
Invasive cancer rate (Used to calculate ICDR)	.	.%	(/)	.	100.00%	(25 /25)	.	75.48%	(7,396 /9,798)	.	76.42%	(7,697 /10,072)
ACRad 8: Minimal cancer rate	.	.%	(/)	.	.%	(/)	.	72.62%	(3,830 /5,274)	.	52.40%	(4,980 /9,504)
ACRad 7: Nodal status negative rate	.	.%	(/)	.	0.00%	(0 /21)	.	87.60%	(3,023 /3,451)	.	75.95%	(5,629 /7,411)
PQRS 146: Inappropriate use of BI-RADS 3	.	0.00%	(0 /146)	.	0.29%	(30 /10,214)	.	0.29%	(6,775 /2,359,100)	.		

To learn more about the Qualified Clinical Data Registry (QCDR) option please click below
http://www.acr.org/Quality-Safety/National-Radiology-Data-Registry/Qualified-Clinical-Data-Registry

NCI-funded Breast Cancer Surveillance Consortium (BCSC) data on screening mammograms performed 2002-2006. BCSC benchmark data are calculated using screen-detected cancers; NMD data may include some interval cancers.

QCDR Measures: Abnormal Interpretations and Cancers for Screening Mammography
Physician 1104033950: January 2015 - December 2015
Follow up available through September 30, 2016

Measure		1104033950 Rate	(Num-Den)		Facility 100853 Rate	(Num-Den)		All NMD facilities (N=274) Rate	(Num-Den)		BCSC benchmark* Rate	(Num-Den)
All exams	.	.	2,050	.	.	10,214	.	.	2,359,219	.	.	2,410,932
ACRad 5: Abnormal interpretation and recall rate	.	14.20%	(291 /2,050)	.	11.02%	(1,126 /10,214)	.	10.00%	(235,908 /2,359,219)	.	10.95%	(263,905 /2,410,932)
ACRad 6: Cancers and PPV2	.	13.33%	(2 /15)	.	28.75%	(23 /80)	.	21.30%	(7,868 /36,946)	.	22.90%	(7,613 /33,239)
ACRad 3: Cancers and CDR per 1000	.	0.98	(2 /2,050)	.	2.45	(25 /10,214)	.	4.16	(9,805 /2,359,219)	.	4.18	(10,072 /2,410,932)
ACRad 4: Invasive cancers and ICDR per 1000	.	0.98	(2 /2,050)	.	2.45	(25 /10,214)	.	3.13	(7,396 /2,359,219)	.		
Invasive cancer rate (Used to calculate ICDR)	.	100.00%	(2 /2)	.	100.00%	(25 /25)	.	75.48%	(7,396 /9,798)	.	76.42%	(7,697 /10,072)
ACRad 8: Minimal cancer rate	.	.%	(/)	.	.%	(/)	.	72.62%	(3,830 /5,274)	.	52.40%	(4,980 /9,504)
ACRad 7: Nodal status negative rate	.	0.00%	(0 /2)	.	0.00%	(0 /21)	.	87.60%	(3,023 /3,451)	.	75.95%	(5,629 /7,411)
PQRS 146: Inappropriate use of BI-RADS 3	.	0.54%	(11 /2,050)	.	0.29%	(30 /10,214)	.	0.29%	(6,775 /2,359,100)	.		

To learn more about the Qualified Clinical Data Registry (QCDR) option please click below

http://www.acr.org/Quality-Safety/National-Radiology-Data-Registry/Qualified-Clinical-Data-Registry

NCI-funded Breast Cancer Surveillance Consortium (BCSC) data on screening mammograms performed 2002-2006. BCSC benchmark data are calculated using screen-detected cancers; NMD data may include some interval cancers.

QCDR Measures: Abnormal Interpretations and Cancers for Screening Mammography
Physician 1235112152: January 2015 - December 2015
Follow up available through September 30, 2016

Measure		1235112152 Rate	(Num-Den)		Facility 100853 Rate	(Num-Den)		All NMD facilities (N=274) Rate	(Num-Den)		BCSC benchmark* Rate	(Num-Den)
All exams	.	.	2,164	.	.	10,214	.	.	2,359,219	.	.	2,410,932
ACRad 5: Abnormal interpretation and recall rate	.	9.43%	(204 /2,164)	.	11.02%	(1,126 /10,214)	.	10.00%	(235,908 /2,359,219)	.	10.95%	(263,905 /2,410,932)
ACRad 6: Cancers and PPV2	.	35.29%	(6 /17)	.	28.75%	(23 /80)	.	21.30%	(7,868 /36,946)	.	22.90%	(7,613 /33,239)
ACRad 3: Cancers and CDR per 1000	.	3.23	(7 /2,164)	.	2.45	(25 /10,214)	.	4.16	(9,805 /2,359,219)	.	4.18	(10,072 /2,410,932)
ACRad 4: Invasive cancers and ICDR per 1000	.	3.23	(7 /2,164)	.	2.45	(25 /10,214)	.	3.13	(7,396 /2,359,219)	.		
Invasive cancer rate (Used to calculate ICDR)	.	100.00%	(7 /7)	.	100.00%	(25 /25)	.	75.48%	(7,396 /9,798)	.	76.42%	(7,697 /10,072)
ACRad 8: Minimal cancer rate	.	.%	(/)	.	.%	(/)	.	72.62%	(3,830 /5,274)	.	52.40%	(4,980 /9,504)
ACRad 7: Nodal status negative rate	.	0.00%	(0 /6)	.	0.00%	(0 /21)	.	87.60%	(3,023 /3,451)	.	75.95%	(5,629 /7,411)
PQRS 146: Inappropriate use of BI-RADS 3	.	0.23%	(5 /2,164)	.	0.29%	(30 /10,214)	.	0.29%	(6,775 /2,359,100)	.		

To learn more about the Qualified Clinical Data Registry (QCDR) option please click below

http://www.acr.org/Quality-Safety/National-Radiology-Data-Registry/Qualified-Clinical-Data-Registry

NCI-funded Breast Cancer Surveillance Consortium (BCSC) data on screening mammograms performed 2002-2006. BCSC benchmark data are calculated using screen-detected cancers; NMD data may include some interval cancers.

QCDR Measures: Abnormal Interpretations and Cancers for Screening Mammography
Physician 1619948387: January 2015 - December 2015
Follow up available through September 30, 2016

Measure	1619948387 Rate	(Num-Den)	Facility 100853 Rate	(Num-Den)	All NMD facilities (N=274) Rate	(Num-Den)	BCSC benchmark* Rate	(Num-Den)
All exams	.	1,245	.	10,214	.	2,359,219	.	2,410,932
ACRad 5: Abnormal interpretation and recall rate	12.05%	(150 /1,245)	11.02%	(1,126 /10,214)	10.00%	(235,908 /2,359,219)	10.95%	(263,905 /2,410,932)
ACRad 6: Cancers and PPV2	0.00%	(0 /13)	28.75%	(23 /80)	21.30%	(7,868 /36,946)	22.90%	(7,613 /33,239)
ACRad 3: Cancers and CDR per 1000	0.00	(0 /1,245)	2.45	(25 /10,214)	4.16	(9,805 /2,359,219)	4.18	(10,072 /2,410,932)
ACRad 4: Invasive cancers and ICDR per 1000	0.00	(0 /1,245)	2.45	(25 /10,214)	3.13	(7,396 /2,359,219)		
Invasive cancer rate (Used to calculate ICDR)	.%	(/)	100.00%	(25 /25)	75.48%	(7,396 /9,798)	76.42%	(7,697 /10,072)
ACRad 8: Minimal cancer rate	.%	(/)	.%	(/)	72.62%	(3,830 /5,274)	52.40%	(4,980 /9,504)
ACRad 7: Nodal status negative rate	.%	(/)	0.00%	(0 /21)	87.60%	(3,023 /3,451)	75.95%	(5,629 /7,411)
PQRS 146: Inappropriate use of BI-RADS 3	0.32%	(4 /1,245)	0.29%	(30 /10,214)	0.29%	(6,775 /2,359,100)		

To learn more about the Qualified Clinical Data Registry (QCDR) option please click below

http://www.acr.org/Quality-Safety/National-Radiology-Data-Registry/Qualified-Clinical-Data-Registry

NCI-funded Breast Cancer Surveillance Consortium (BCSC) data on screening mammograms performed 2002-2006. BCSC benchmark data are calculated using screen-detected cancers; NMD data may include some interval cancers.

QCDR Measures: Abnormal Interpretations and Cancers for Screening Mammography
Physician 1841243599: January 2015 - December 2015
Follow up available through September 30, 2016

Measure		1841243599 Rate	(Num-Den)		Facility 100853 Rate	(Num-Den)		All NMD facilities (N=274) Rate	(Num-Den)		BCSC benchmark* Rate	(Num-Den)
All exams	.	.	2,178	.	.	10,214	.	.	2,359,219	.	.	2,410,932
ACRad 5: Abnormal interpretation and recall rate	.	7.94%	(173 /2,178)	.	11.02%	(1,126 /10,214)	.	10.00%	(235,908 /2,359,219)	.	10.95%	(263,905 /2,410,932)
ACRad 6: Cancers and PPV2	.	55.00%	(11 /20)	.	28.75%	(23 /80)	.	21.30%	(7,868 /36,946)	.	22.90%	(7,613 /33,239)
ACRad 3: Cancers and CDR per 1000	.	5.05	(11 /2,178)	.	2.45	(25 /10,214)	.	4.16	(9,805 /2,359,219)	.	4.18	(10,072 /2,410,932)
ACRad 4: Invasive cancers and ICDR per 1000	.	5.05	(11 /2,178)	.	2.45	(25 /10,214)	.	3.13	(7,396 /2,359,219)	.		
Invasive cancer rate (Used to calculate ICDR)	.	100.00%	(11 /11)	.	100.00%	(25 /25)	.	75.48%	(7,396 /9,798)	.	76.42%	(7,697 /10,072)
ACRad 8: Minimal cancer rate	.	.%	(/)	.	.%	(/)	.	72.62%	(3,830 /5,274)	.	52.40%	(4,980 /9,504)
ACRad 7: Nodal status negative rate	.	0.00%	(0 /9)	.	0.00%	(0 /21)	.	87.60%	(3,023 /3,451)	.	75.95%	(5,629 /7,411)
PQRS 146: Inappropriate use of BI-RADS 3	.	0.09%	(2 /2,178)	.	0.29%	(30 /10,214)	.	0.29%	(6,775 /2,359,100)	.		

To learn more about the Qualified Clinical Data Registry (QCDR) option please click below
http://www.acr.org/Quality-Safety/National-Radiology-Data-Registry/Qualified-Clinical-Data-Registry

NCI-funded Breast Cancer Surveillance Consortium (BCSC) data on screening mammograms performed 2002-2006. BCSC benchmark data are calculated using screen-detected cancers; NMD data may include some interval cancers.

QCDR Measures: Abnormal Interpretations and Cancers for Screening Mammography
Physician 1912950429: January 2015 - December 2015
## Follow up available through September 30, 2016

	1912950429			Facility 100853			All NMD facilities (N=274)			BCSC benchmark*	
Measure	Rate	(Num-Den)		Rate	(Num-Den)		Rate	(Num-Den)		Rate	(Num-Den)
All exams	.	.	2,431	.	.	10,214	.	.	2,359,219	.	.	2,410,932
ACRad 5: Abnormal interpretation and recall rate	.	11.68%	(284 /2,431)	.	11.02%	(1,126 /10,214)	.	10.00%	(235,908 /2,359,219)	.	10.95%	(263,905 /2,410,932)
ACRad 6: Cancers and PPV2	.	30.77%	(4 /13)	.	28.75%	(23 /80)	.	21.30%	(7,868 /36,946)	.	22.90%	(7,613 /33,239)
ACRad 3: Cancers and CDR per 1000	.	2.06	(5 /2,431)	.	2.45	(25 /10,214)	.	4.16	(9,805 /2,359,219)	.	4.18	(10,072 /2,410,932)
ACRad 4: Invasive cancers and ICDR per 1000	.	2.06	(5 /2,431)	.	2.45	(25 /10,214)	.	3.13	(7,396 /2,359,219)	.		
Invasive cancer rate (Used to calculate ICDR)	.	100.00%	(5 /5)	.	100.00%	(25 /25)	.	75.48%	(7,396 /9,798)	.	76.42%	(7,697 /10,072)
ACRad 8: Minimal cancer rate	.	.%	(/)	.	.%	(/)	.	72.62%	(3,830 /5,274)	.	52.40%	(4,980 /9,504)
ACRad 7: Nodal status negative rate	.	0.00%	(0 /4)	.	0.00%	(0 /21)	.	87.60%	(3,023 /3,451)	.	75.95%	(5,629 /7,411)
PQRS 146: Inappropriate use of BI-RADS 3	.	0.33%	(8 /2,431)	.	0.29%	(30 /10,214)	.	0.29%	(6,775 /2,359,100)	.		

To learn more about the Qualified Clinical Data Registry (QCDR) option please click below
http://www.acr.org/Quality-Safety/National-Radiology-Data-Registry/Qualified-Clinical-Data-Registry

NCI-funded Breast Cancer Surveillance Consortium (BCSC) data on screening mammograms performed 2002-2006. BCSC benchmark data are calculated using screen-detected cancers; NMD data may include some interval cancers.

Section 2: Preliminary data on exams performed in the most recent 12 months. (Includes uploaded data through September 30, 2016)

QCDR Measures: Abnormal Interpretations and Cancers for Screening Mammography
January 2016 - September 2016: Comparison to all NMD facilities and BCSC benchmarks

Measure		Rate	(Num-Den)
	All NMD facilities (N=274)		
All exams	.	.	1,225,921
ACRad 5: Abnormal interpretation and recall rate	.	10.00%	(122,547 /1,225,921)
ACRad 6: Cancers and PPV2	.	20.73%	(3,661 /17,658)
ACRad 3: Cancers and CDR per 1000	.	3.87	(4,745 /1,225,921)
ACRad 4: Invasive cancers and ICDR per 1000	.	3.00	(3,673 /1,225,921)
Invasive cancer rate (Used to calculate ICDR)	.	77.42%	(3,673 /4,744)
ACRad 8: Minimal cancer rate	.	74.82%	(1,780 /2,379)
ACRad 7: Nodal status negative rate	.	85.01%	(1,293 /1,521)
PQRS 146: Inappropriate use of BI-RADS 3	.	0.25%	(3,012 /1,219,812)

To learn more about the Qualified Clinical Data Registry (QCDR) option please click below
http://www.acr.org/Quality-Safety/National-Radiology-Data-Registry/Qualified-Clinical-Data-Registry

PRELIMINARY OUTCOME DATA; FINAL DATA WILL BE AVAILABLE 12 MONTHS AFTER EXAM DATE
QCDR Measures: Abnormal Interpretations and Cancers for Screening Mammography
Physician 1013909175: January, 2016 - September 2016

Measure		Rate	(Num-Den)
All NMD facilities (N=274)			
All exams	.	.	1,225,921
ACRad 5: Abnormal interpretation and recall rate	.	10.00%	(122,547 /1,225,921)
ACRad 6: Cancers and PPV2	.	20.73%	(3,661 /17,658)
ACRad 3: Cancers and CDR per 1000	.	3.87	(4,745 /1,225,921)
ACRad 4: Invasive cancers and ICDR per 1000	.	3.00	(3,673 /1,225,921)
Invasive cancer rate (Used to calculate ICDR)	.	77.42%	(3,673 /4,744)
ACRad 8: Minimal cancer rate	.	74.82%	(1,780 /2,379)
ACRad 7: Nodal status negative rate	.	85.01%	(1,293 /1,521)
PQRS 146: Inappropriate use of BI-RADS 3	.	0.25%	(3,012 /1,219,812)

To learn more about the Qualified Clinical Data Registry (QCDR) option please click below
http://www.acr.org/Quality-Safety/National-Radiology-Data-Registry/Qualified-Clinical-Data-Registry

PRELIMINARY OUTCOME DATA; FINAL DATA WILL BE AVAILABLE 12 MONTHS AFTER EXAM DATE
QCDR Measures: Abnormal Interpretations and Cancers for Screening Mammography
Physician 1104033950: January, 2016 - September 2016

Measure		All NMD facilities (N=274)	
		Rate	(Num-Den)
All exams	.	.	1,225,921
ACRad 5: Abnormal interpretation and recall rate	.	10.00%	(122,547 /1,225,921)
ACRad 6: Cancers and PPV2	.	20.73%	(3,661 /17,658)
ACRad 3: Cancers and CDR per 1000	.	3.87	(4,745 /1,225,921)
ACRad 4: Invasive cancers and ICDR per 1000	.	3.00	(3,673 /1,225,921)
Invasive cancer rate (Used to calculate ICDR)	.	77.42%	(3,673 /4,744)
ACRad 8: Minimal cancer rate	.	74.82%	(1,780 /2,379)
ACRad 7: Nodal status negative rate	.	85.01%	(1,293 /1,521)
PQRS 146: Inappropriate use of BI-RADS 3	.	0.25%	(3,012 /1,219,812)

To learn more about the Qualified Clinical Data Registry (QCDR) option please click below
http://www.acr.org/Quality-Safety/National-Radiology-Data-Registry/Qualified-Clinical-Data-Registry

PRELIMINARY OUTCOME DATA; FINAL DATA WILL BE AVAILABLE 12 MONTHS AFTER EXAM DATE
QCDR Measures: Abnormal Interpretations and Cancers for Screening Mammography
Physician 1235112152: January, 2016 - September 2016

Measure		All NMD facilities (N=274)	
		Rate	(Num-Den)
All exams	.	.	1,225,921
ACRad 5: Abnormal interpretation and recall rate	.	10.00%	(122,547 /1,225,921)
ACRad 6: Cancers and PPV2	.	20.73%	(3,661 /17,658)
ACRad 3: Cancers and CDR per 1000	.	3.87	(4,745 /1,225,921)
ACRad 4: Invasive cancers and ICDR per 1000	.	3.00	(3,673 /1,225,921)
Invasive cancer rate (Used to calculate ICDR)	.	77.42%	(3,673 /4,744)
ACRad 8: Minimal cancer rate	.	74.82%	(1,780 /2,379)
ACRad 7: Nodal status negative rate	.	85.01%	(1,293 /1,521)
PQRS 146: Inappropriate use of BI-RADS 3	.	0.25%	(3,012 /1,219,812)

To learn more about the Qualified Clinical Data Registry (QCDR) option please click below
http://www.acr.org/Quality-Safety/National-Radiology-Data-Registry/Qualified-Clinical-Data-Registry

PRELIMINARY OUTCOME DATA; FINAL DATA WILL BE AVAILABLE 12 MONTHS AFTER EXAM DATE
QCDR Measures: Abnormal Interpretations and Cancers for Screening Mammography
Physician 1619948387: January, 2016 - September 2016

Measure		Rate	(Num-Den)
	All NMD facilities (N=274)		
All exams	.	.	1,225,921
ACRad 5: Abnormal interpretation and recall rate	.	10.00%	(122,547 /1,225,921)
ACRad 6: Cancers and PPV2	.	20.73%	(3,661 /17,658)
ACRad 3: Cancers and CDR per 1000	.	3.87	(4,745 /1,225,921)
ACRad 4: Invasive cancers and ICDR per 1000	.	3.00	(3,673 /1,225,921)
Invasive cancer rate (Used to calculate ICDR)	.	77.42%	(3,673 /4,744)
ACRad 8: Minimal cancer rate	.	74.82%	(1,780 /2,379)
ACRad 7: Nodal status negative rate	.	85.01%	(1,293 /1,521)
PQRS 146: Inappropriate use of BI-RADS 3	.	0.25%	(3,012 /1,219,812)

PRELIMINARY OUTCOME DATA; FINAL DATA WILL BE AVAILABLE 12 MONTHS AFTER EXAM DATE
QCDR Measures: Abnormal Interpretations and Cancers for Screening Mammography
Physician 1841243599: January, 2016 - September 2016

Measure		Rate	(Num-Den)
		All NMD facilities (N=274)	
All exams	.	.	1,225,921
ACRad 5: Abnormal interpretation and recall rate	.	10.00%	(122,547 /1,225,921)
ACRad 6: Cancers and PPV2	.	20.73%	(3,661 /17,658)
ACRad 3: Cancers and CDR per 1000	.	3.87	(4,745 /1,225,921)
ACRad 4: Invasive cancers and ICDR per 1000	.	3.00	(3,673 /1,225,921)
Invasive cancer rate (Used to calculate ICDR)	.	77.42%	(3,673 /4,744)
ACRad 8: Minimal cancer rate	.	74.82%	(1,780 /2,379)
ACRad 7: Nodal status negative rate	.	85.01%	(1,293 /1,521)
PQRS 146: Inappropriate use of BI-RADS 3	.	0.25%	(3,012 /1,219,812)

To learn more about the Qualified Clinical Data Registry (QCDR) option please click below
http://www.acr.org/Quality-Safety/National-Radiology-Data-Registry/Qualified-Clinical-Data-Registry

PRELIMINARY OUTCOME DATA; FINAL DATA WILL BE AVAILABLE 12 MONTHS AFTER EXAM DATE
QCDR Measures: Abnormal Interpretations and Cancers for Screening Mammography
Physician 1912950429: January, 2016 - September 2016

Measure		Rate	(Num-Den)
	All NMD facilities (N=274)		
All exams	.	.	1,225,921
ACRad 5: Abnormal interpretation and recall rate	.	10.00%	(122,547 /1,225,921)
ACRad 6: Cancers and PPV2	.	20.73%	(3,661 /17,658)
ACRad 3: Cancers and CDR per 1000	.	3.87	(4,745 /1,225,921)
ACRad 4: Invasive cancers and ICDR per 1000	.	3.00	(3,673 /1,225,921)
Invasive cancer rate (Used to calculate ICDR)	.	77.42%	(3,673 /4,744)
ACRad 8: Minimal cancer rate	.	74.82%	(1,780 /2,379)
ACRad 7: Nodal status negative rate	.	85.01%	(1,293 /1,521)
PQRS 146: Inappropriate use of BI-RADS 3	.	0.25%	(3,012 /1,219,812)

To learn more about the Qualified Clinical Data Registry (QCDR) option please click below
http://www.acr.org/Quality-Safety/National-Radiology-Data-Registry/Qualified-Clinical-Data-Registry

Promote your participation in NRDR™!
Download your marketing toolkit today.

acr.org/NMDtoolkit

CONTACT US
1.800.227.5463, ext. 3535
nrdr@acr.org | nrdr.acr.org

AMERICAN COLLEGE OF RADIOLOGY
NRDR
NMD®
NATIONAL MAMMOGRAPHY DATABASE
PARTICIPANT